Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Squamous Cell Carcinoma 12 Esophageal Neoplasms 9 Uterine Cervical Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Lymphatic Metastasis 2 Uterine Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Solid Tumor Cancer 1 Recurrence 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ductal, Breast 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 151 Dexamethasone 140 Rituximab 83 fludarabine 78 Cytarabine 69 Lenalidomide 68 Bortezomib 63 fludarabine phosphate 62 Gemcitabine 62 venetoclax 54 Etoposide 53 pembrolizumab 52 pomalidomide 48 Paclitaxel 48 Cisplatin 47 Carboplatin 47 Peripheral Blood Stem Cell Transplantation 46 Filgrastim 40 Radiotherapy 39 Calcium Dobesilate 36 Busulfan 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 29 Vincristine 28 Temozolomide 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × TP protocol × Clear all

NCT01405235 2012-04-12

AGO-Zervix-1

Institut fuer Frauengesundheit

Phase 3 Unknown

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡